MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ
10.98
+0.01
+0.09%
Pre Market: 10.98 0 0.00% 06:12 11/17 EST
OPEN
10.88
PREV CLOSE
10.97
HIGH
11.40
LOW
10.76
VOLUME
50
TURNOVER
0
52 WEEK HIGH
309.60
52 WEEK LOW
8.29
MARKET CAP
67.16M
P/E (TTM)
-0.3094
1D
5D
1M
3M
1Y
5Y
1D
Gossamer Bio Files Prospectus Related To The Proposed Resale Or Other Disposition By The Selling Securityholders Of Up To 1,697,363 Shares Of Common Stock
Benzinga · 15h ago
Gossamer Bio registers to sell 1.7M shares of common stock for holders
TipRanks · 15h ago
Weekly Report: what happened at GOSS last week (1109-1113)?
Weekly Report · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Conmed (CNMD) and Gossamer Bio (GOSS)
TipRanks · 3d ago
Guggenheim Sticks to Their Hold Rating for Gossamer Bio (GOSS)
TipRanks · 5d ago
Gossamer Bio is Chardan's top small-cap pick for 2027
Seeking Alpha · 5d ago
Gossamer Bio Analysts Slash Their Forecasts Following Q3 Results
Benzinga · 5d ago
Gossamer Bio Is Maintained at Overweight by Piper Sandler
Dow Jones · 5d ago
More
About GOSS
Gossamer Bio, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The Company's lead product candidate is Seralutinib (GB002), is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR. Seralutinib is designed to inhibit multiple kinases in the pathology of PAH. The PDGFR is a tyrosine kinase receptor which, when activated by its agonist, induces cellular proliferation. The c-KIT pathway was also identified as a factor involved in pulmonary vascular remodeling, particularly in the cells implicated in perivascular inflammation.

Webull offers Gossamer Bio Inc stock information, including NASDAQ: GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.